Navigation Links
Intestinal protein may have role in ADHD, other neurological disorders
Date:8/12/2011

CINCINNATI A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD (Attention Deficit Hyperactivity Disorder) other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

Scientists have for the last quarter century studied the intestinal membrane receptor protein, guanylyl cyclase-C (GC-C) for its role in diarrheal disease and other intestinal functions, according to Mitchell Cohen, M.D., U.S. author on the study and director of Gastroenterology, Hepatology and Nutrition at Cincinnati Children's Hospital Medical Center. In fact, it had been thought that GC-C was found primarily in the intestine.

In the current study, scientists in China who collaborated with Dr. Cohen discovered that the receptor is also expressed in critical areas of the brain. The senior author on the study is Dr. Minmin Luo, a researcher at the National Institute of Biological Sciences and Tsinghua University in Beijing.

Using a mouse model developed in Dr. Ralph Giannella's laboratory at the University of Cincinnati, in which the GC-C receptor is deleted, or knocked out, the researchers found the mice exhibit hyperactivity and attention deficits. It is the first time that GC-C has been linked to neuropsychiatric disorder, according to the researchers.

"We show that the neurons selectively express GC-C and that its activation amplifies the excitatory responses mediated by other receptors on dopamine neurons in the midbrain," said Dr. Luo. "Working through a protein kinase called PKG, GC-C activity increases brain dopamine levels and thus regulate mouse attention and activity level."

When the researchers treated the GC-C knockout mice with amphetamine-based ADHD medication and a PKG activator, it reversed their hyperactive, inattentive behavior.

"The results indicate important behavioral and physiological functions for the GC-C/PKG signaling pathway in the brain," said Dr. Luo. "The data also suggest new therapeutic targets for neuropsychiatric disorders related to malfunctions of midbrain dopamine receptors."

One of the most prevalent human behavioral disorders, ADHD has been linked to imbalances in the dopamine system. The researchers noted in the study that its findings mice exhibiting reduced dopamine levels and related behavioral problems are consistent with the biochemical characteristics of human ADHD.

"This could make the GC-C knockout mouse a good research model for ADHD and other behavioral disorders," said Dr. Cohen. "Efforts to develop activators or inhibitors of the GC-C/PKG signaling pathway may lead to novel treatments for other disorders, such schizophrenia, Parkinson's disease and addiction."


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related biology technology :

1. New screening techniques, treatments shed light on gastrointestinal disorders in children
2. FDA Grants Fast Track Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
3. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
4. NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
7. Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohns Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports
8. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
9. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
10. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
11. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The ... hobbyists, and the University Aviation Association (UAA), the unifying voice for collegiate aviation ... Challenge will encourage teamwork, competition, and success through a STEM-based education platform. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to ... from hay fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are ...
(Date:6/22/2017)... ... 22, 2017 , ... The first human cell line HeLa, established in 1951, ... on cross-contamination of human cell lines with HeLa cells were published. Until recently, cross-contamination ... labs and is associated with dramatic consequences for research. , In this educational ...
(Date:6/20/2017)... ... 20, 2017 , ... Biologist Dawn Maslar MS has found a biomarker that ... Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding True ... ”The logical next step, in my estimation, was to scientifically track the evidence of ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):